Eli Lilly Enters the Obesity Battle: New Pill Poised to Challenge Novo Nordisk’s Oral Wegovy, Shaking Up the Weight Loss Market and Investor Landscape
Eli Lilly’s Obesity Pill: Underwhelming Trial Data but a Potential Game-Changer in the Weight Loss Market Eli Lilly’s recent trial results for its obesity pill, orforglipron, sent its stock tumbling 13% initially, reflecting Wall Street’s … Read more